2022.12.23

We are pleased to announce J-Pharmaʼs lead oncology product candidate, Nanvuranlat will feature at the upcoming ASCO Gastrointestinal Cancers Symposium, to be held in San Francisco on 19-21 January 2023

December 23,2022
J-Pharma Co., Ltd.

We are pleased to announce J-Pharmaʼs lead oncology product candidate, Nanvuranlat will feature at the upcoming ASCO Gastrointestinal Cancers Symposium, to be held in San Francisco on 19-21 January 2023.

  1. Presentation Details: Rapid Abstract Session B:
  2. Rapid Abstract Session B:
    Date/Time: January 20,2023 7:10 -7:15 am PST
    Place: Level 3, Ballroom
  3. Poster Session
    Date/Time: January 20,2023 12:00 – 13:30 pm PST
    Place: Level 1, West Hall
    Abstract Number: 494
  4. Abstract Title: Nanvuranlat, an L-type amino acid transporter (LAT1) inhibitor for patients with pretreated advanced refractory biliary tract cancer (BTC): Primary endpoint results of a randomized, double-blind, placebo-controlled phase 2 study

Contact: Tomohiro Yuzawa, Director, Corporate Management
Tel: 045-506-1155
info@j-pharma.com

Back